🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million infections each year. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per data published in a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves an injection and a pill. The trial enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in many developing nations.

Doctors directly involved have voiced positive views. Having a one-pill regimen like this is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.